GLP-1 Medications and Heart Health: What the SELECT Trial Showed

For years, the conversation around GLP-1 medications focused almost entirely on weight loss and blood sugar control. Then came the SELECT trial, and everything changed.

Published in the *New England Journal of Medicine* in November 2023, the SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was the first large-scale randomized controlled trial to demonstrate that a GLP-1 medication reduces major cardiovascular events in people with obesity who do not have diabetes.

What the SELECT Trial Found

The SELECT trial enrolled 17,604 adults with established cardiovascular disease and a BMI of 27 or higher, but without type 2 diabetes. Participants were randomized to weekly subcutaneous semaglutide 2.4 mg or placebo for a median of 3.3 years.

The primary endpoint was major adverse cardiovascular events (MACE): cardiovascular death, non-fatal heart attack, or non-fatal stroke.

Key results:

• Semaglutide reduced MACE by 20% compared to placebo (6.5% vs 8.0%)
• The benefit was consistent across all prespecified subgroups
• Effects on cardiovascular outcomes appeared early and continued to diverge over the study duration
• Mean weight loss in the semaglutide group was approximately 9.4% of body weight

This is a landmark finding. It establishes that semaglutide's cardiovascular protection extends beyond its effects in diabetic patients, and beyond just weight loss metrics.

Why This Matters Beyond Weight Loss

The SELECT trial adds to a growing body of evidence showing that GLP-1 receptor agonists provide cardiovascular benefits through multiple mechanisms that are partially independent of weight loss:

Anti-inflammatory effects: Obesity drives chronic systemic inflammation, a major contributor to atherosclerosis. Semaglutide appears to reduce inflammatory markers including CRP and interleukin-6.

Direct cardiac effects: GLP-1 receptors are expressed in cardiac tissue. Animal studies and smaller human trials suggest GLP-1 agonism may improve myocardial glucose uptake, reduce cardiac oxidative stress, and have direct anti-atherosclerotic effects on vessel walls.

Blood pressure and lipids: The trial confirmed modest reductions in systolic blood pressure and improvements in lipid profiles, contributing to reduced overall cardiovascular risk.

STEP-HFpEF: GLP-1 in Heart Failure

In a separate trial published concurrently in 2023, the STEP-HFpEF study evaluated semaglutide in patients with heart failure with preserved ejection fraction (HFpEF), a condition strongly linked to obesity and highly resistant to treatment.

The results were striking: semaglutide produced significant improvements in symptoms, exercise function, and quality of life compared to placebo. Patients also experienced meaningful weight loss and reductions in inflammatory markers. HFpEF is increasingly recognized as an "obesity phenotype" of heart failure, and these results suggest GLP-1 therapy may represent a meaningful treatment advance.

Earlier Evidence: SUSTAIN-6 in Diabetes

The cardiovascular story for semaglutide began earlier with the SUSTAIN-6 trial in patients with type 2 diabetes, which found a 26% reduction in MACE at lower doses (0.5-1.0 mg/week) over 2 years. The SELECT trial extended this protection to a much broader population (people without diabetes) at the higher 2.4 mg dose used for weight management.

Who This Research Applies To

These findings are most directly relevant for individuals who:

• Have a history of heart attack, stroke, or established cardiovascular disease
• Have obesity (BMI ≥27) alongside cardiovascular risk factors
• Are seeking weight management approaches with demonstrated systemic health benefits beyond the scale

For people managing weight primarily for appearance or metabolic reasons without cardiovascular disease history, the cardiovascular benefits represent an additional health dividend, not the primary indication.

Important Context

The SELECT trial used semaglutide 2.4 mg weekly, which is the dose in Wegovy, not the 0.5-1.0 mg doses in Ozempic. Compounded semaglutide can be dosed to equivalent levels, but the trial data applies to the studied dose in the studied population.

Additionally, these benefits were observed in people with prior cardiovascular events. Whether the same cardiovascular protection applies to primary prevention (people without prior events) remains an active research question.

The Bottom Line

The SELECT trial fundamentally changed the risk-benefit calculus for GLP-1 therapy. What was previously a weight management medication has been shown, at the highest level of evidence, to protect hearts. For the right patient, semaglutide is no longer just a weight loss drug; it is a cardiovascular risk reduction therapy.

*This article summarizes published research and does not constitute medical advice. Always consult a qualified healthcare provider to discuss whether GLP-1 therapy is appropriate for your individual health situation. Results may vary.*

References

1. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med.* 2023 Dec. PMID 37952131. [https://pubmed.ncbi.nlm.nih.gov/37952131/](https://pubmed.ncbi.nlm.nih.gov/37952131/)
2. Kosiborod MN, et al. Semaglutide versus placebo in patients with heart failure with mildly reduced or preserved ejection fraction. *Lancet.* 2024 Sep. PMID 39222642. [https://pubmed.ncbi.nlm.nih.gov/39222642/](https://pubmed.ncbi.nlm.nih.gov/39222642/)
3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). *N Engl J Med.* 2021 Mar. PMID 33567185. [https://pubmed.ncbi.nlm.nih.gov/33567185/](https://pubmed.ncbi.nlm.nih.gov/33567185/)